Haleon plc

NYSE:HLN USA Drug Manufacturers - Specialty & Generic
Market Cap
$47.20 Billion
Market Cap Rank
#434 Global
#343 in USA
Share Price
$10.60
Change (1 day)
+1.34%
52-Week Range
$8.72 - $11.41
All Time High
$11.41
About

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Aquafresh, and Biotene… Read more

Haleon plc (HLN) - Net Assets

Latest net assets as of June 2025: $16.00 Billion USD

Based on the latest financial reports, Haleon plc (HLN) has net assets worth $16.00 Billion USD as of June 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($31.83 Billion) and total liabilities ($15.83 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $16.00 Billion
% of Total Assets 50.26%
Annual Growth Rate -9.95%
5-Year Change -38.13%
10-Year Change N/A
Growth Volatility 14.84

Haleon plc - Net Assets Trend (2019–2024)

This chart illustrates how Haleon plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Haleon plc (2019–2024)

The table below shows the annual net assets of Haleon plc from 2019 to 2024.

Year Net Assets Change
2024-12-31 $16.22 Billion -3.02%
2023-12-31 $16.73 Billion +1.65%
2022-12-31 $16.46 Billion -37.85%
2021-12-31 $26.48 Billion +0.98%
2020-12-31 $26.22 Billion -4.34%
2019-12-31 $27.41 Billion --

Equity Component Analysis

This analysis shows how different components contribute to Haleon plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 434.1% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings $27.27 Billion 168.70%
Common Stock $91.00 Million 0.56%
Other Comprehensive Income $-11.08 Billion -68.55%
Total Equity $16.17 Billion 100.00%

Haleon plc Competitors by Market Cap

The table below lists competitors of Haleon plc ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Haleon plc's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 16,606,000,000 to 16,166,000,000, a change of -440,000,000 (-2.6%).
  • Net income of 1,442,000,000 contributed positively to equity growth.
  • Dividend payments of 570,000,000 reduced retained earnings.
  • Share repurchases of 121,000,000 reduced equity.
  • Other comprehensive income decreased equity by 121,000,000.
  • Other factors decreased equity by 1,070,000,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $1.44 Billion +8.92%
Dividends Paid $570.00 Million -3.53%
Share Repurchases $121.00 Million -0.75%
Other Comprehensive Income $-121.00 Million -0.75%
Other Changes $-1.07 Billion -6.62%
Total Change $- -2.65%

Book Value vs Market Value Analysis

This analysis compares Haleon plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 3.01x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has increased from 1.79x to 3.01x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2019-12-31 $5.92 $10.60 x
2020-12-31 $5.66 $10.60 x
2021-12-31 $5.71 $10.60 x
2022-12-31 $3.54 $10.60 x
2023-12-31 $3.59 $10.60 x
2024-12-31 $3.52 $10.60 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Haleon plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 8.92%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 12.84%
  • • Asset Turnover: 0.33x
  • • Equity Multiplier: 2.12x
  • Recent ROE (8.92%) is above the historical average (5.63%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2019 2.40% 7.72% 0.24x 1.31x $-2.08 Billion
2020 4.38% 11.58% 0.29x 1.31x $-1.47 Billion
2021 5.27% 14.56% 0.28x 1.31x $-1.25 Billion
2022 6.49% 9.76% 0.31x 2.13x $-573.10 Million
2023 6.32% 9.28% 0.33x 2.05x $-611.60 Million
2024 8.92% 12.84% 0.33x 2.12x $-174.60 Million

Industry Comparison

This section compares Haleon plc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $548,450,613
  • Average return on equity (ROE) among peers: -450.37%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Haleon plc (HLN) $16.00 Billion 2.40% 0.99x $49.87 Billion
Ascend Wellness Holdings Inc (AAWH) $142.87 Million -33.75% 5.44x $48.90 Million
AB Science S.A (ABSCF) $10.73 Million -252.65% 3.71x $39.89 Million
Alterola Biotech Inc (ABTI) $4.85K -2005.32% 0.49x $603.58K
Aurora Cannabis Inc (ACB) $2.04 Billion -34.08% 0.34x $199.15 Million
Acreage Holdings Inc (ACRDF) $204.27 Million -30.85% 1.41x $13.48K
Acura Pharmaceuticals Inc (ACUR) $7.90 Million -63.15% 1.15x $13.20K
Agra Ventures Ltd. (AGFAF) $1.51 Million -44.22% 0.06x $298.23K
Allergy Therapeutics plc (AGYTF) $2.07 Million -2084.75% 31.32x $25.30 Million
Aida Pharmaceuticals Inc (AIDA) $6.67 Million 24.51% 2.78x $1.80
Adcock Ingram Holdings Limited (AIHLF) $3.07 Billion 20.55% 0.55x $85.61 Million